Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients

DOI record: { "DOI": "10.7759/cureus.74513", "ISSN": [ "2168-8184" ], "URL": "http://dx.doi.org/10.7759/cureus.74513", "author": [ { "affiliation": [], "family": "García-Méndez", "given": "Jorge O", "sequence": "first" }, { "affiliation": [], "family": "Fernández-Garza", "given": "Luis E", "sequence": "additional" }, { "affiliation": [], "family": "Vallejo-Oviedo", "given": "Karen", "sequence": "additional" }, { "affiliation": [], "family": "Gómez-Curiel", "given": "Diana I", "sequence": "additional" }, { "affiliation": [], "family": "Barrera-Barrera", "given": "Silvia A", "sequence": "additional" }, { "affiliation": [], "family": "Ordaz-Cuellar", "given": "Rosario", "sequence": "additional" }, { "affiliation": [], "family": "Sosa-García", "given": "Jesús O", "sequence": "additional" }, { "affiliation": [], "family": "García-Torrentera", "given": "Rogelio A", "sequence": "additional" }, { "affiliation": [], "family": "Cervera", "given": "Eduardo", "sequence": "additional" }, { "affiliation": [], "family": "Barrera-Saldaña", "given": "Hugo A", "sequence": "additional" } ], "container-title": "Cureus", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 11, 26 ] ], "date-time": "2024-11-26T17:43:04Z", "timestamp": 1732642984000 }, "deposited": { "date-parts": [ [ 2024, 11, 26 ] ], "date-time": "2024-11-26T17:43:08Z", "timestamp": 1732642988000 }, "indexed": { "date-parts": [ [ 2024, 11, 27 ] ], "date-time": "2024-11-27T05:35:18Z", "timestamp": 1732685718127, "version": "3.28.2" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 11, 26 ] ] }, "language": "en", "link": [ { "URL": "https://www.cureus.com/articles/237234-clinical-experience-with-ivermectin-and-nitazoxanide-in-the-management-of-covid-19-among-mexican-out--and-inpatients", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.7759", "published": { "date-parts": [ [ 2024, 11, 26 ] ] }, "published-print": { "date-parts": [ [ 2024, 11, 26 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.31005/iajmh.v3i0.89", "article-title": "Neurological aspects that should not be forgotten during the COVID-19 pandemic", "author": "Fernández-Garza LE", "doi-asserted-by": "publisher", "journal-title": "InterAmerican J Med Health", "key": "ref1", "unstructured": "Fernández-Garza LE, Marfil A. Neurological aspects that should not be forgotten during the COVID-19 pandemic. InterAmerican J Med Health. 2020, 3:1-3. 10.31005/iajmh.v3i0.89", "volume": "3", "year": "2020" }, { "DOI": "10.2139/ssrn.3566298", "article-title": "World Health Organization declared a pandemic public health menace: a systematic review of the coronavirus disease 2019 “COVID-19”", "author": "Jebril NM", "doi-asserted-by": "publisher", "journal-title": "Int J Psychosoc Rehabil", "key": "ref2", "unstructured": "Jebril NM. World Health Organization declared a pandemic public health menace: a systematic review of the coronavirus disease 2019 “COVID-19”. Int J Psychosoc Rehabil. 2019, 249:2784-95. 10.2139/ssrn.3566298", "volume": "249", "year": "2019" }, { "DOI": "10.1111/jocn.15314", "article-title": "The potential for COVID-19 to contribute to compassion fatigue in critical care nurses", "author": "Alharbi J", "doi-asserted-by": "publisher", "journal-title": "J Clin Nurs", "key": "ref3", "unstructured": "Alharbi J, Jackson D, Usher K. The potential for COVID-19 to contribute to compassion fatigue in critical care nurses. J Clin Nurs. 2020, 29:2762-4. 10.1111/jocn.15314", "volume": "29", "year": "2020" }, { "DOI": "10.1038/s41429-020-0336-z", "article-title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen", "author": "Heidary F", "doi-asserted-by": "publisher", "journal-title": "J Antibiot (Tokyo)", "key": "ref4", "unstructured": "Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020, 73:593-602. 10.1038/s41429-020-0336-z", "volume": "73", "year": "2020" }, { "DOI": "10.1016/j.ejphar.2020.173748", "article-title": "A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19", "author": "Lokhande AS", "doi-asserted-by": "publisher", "journal-title": "Eur J Pharmacol", "key": "ref5", "unstructured": "Lokhande AS, Devarajan PV. A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19. Eur J Pharmacol. 2021, 891:173748. 10.1016/j.ejphar.2020.173748", "volume": "891", "year": "2021" }, { "DOI": "10.1016/j.antiviral.2020.104787", "article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", "author": "Caly L", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res", "key": "ref6", "unstructured": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020, 178:104787. 10.1016/j.antiviral.2020.104787", "volume": "178", "year": "2020" }, { "DOI": "10.1038/s41422-020-0282-0", "article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", "author": "Wang M", "doi-asserted-by": "publisher", "journal-title": "Cell Res", "key": "ref7", "unstructured": "Wang M, Cao R, Zhang L, et al.. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30:269-71. 10.1038/s41422-020-0282-0", "volume": "30", "year": "2020" }, { "DOI": "10.1186/s12879-022-07589-8", "article-title": "Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype", "author": "Marcolino MS", "doi-asserted-by": "publisher", "journal-title": "BMC Infect Dis", "key": "ref8", "unstructured": "Marcolino MS, Meira KC, Guimarães NS, et al.. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infect Dis. 2022, 22:639. 10.1186/s12879-022-07589-8", "volume": "22", "year": "2022" }, { "DOI": "10.1093/qjmed/hcac072", "article-title": "Correction to: Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis", "author": "Deng J", "doi-asserted-by": "publisher", "journal-title": "QJM", "key": "ref9", "unstructured": "Deng J, Zhou F, Ali S, Heybati K, Hou W, Huang E, Wong CY. Correction to: Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2022, 115:706. 10.1093/qjmed/hcac072", "volume": "115", "year": "2022" }, { "DOI": "10.3390/diagnostics11091645", "article-title": "Ivermectin for prophylaxis and treatment of COVID-19: a systematic review and meta-analysis", "author": "Cruciani M", "doi-asserted-by": "publisher", "journal-title": "Diagnostics (Basel)", "key": "ref10", "unstructured": "Cruciani M, Pati I, Masiello F, Malena M, Pupella S, De Angelis V. Ivermectin for prophylaxis and treatment of COVID-19: a systematic review and meta-analysis. Diagnostics (Basel). 2021, 11:14-6. 10.3390/diagnostics11091645", "volume": "11", "year": "2021" }, { "DOI": "10.1093/cid/ciab591", "article-title": "Ivermectin for the treatment of coronavirus disease 2019: a systematic review and meta-analysis of randomized controlled trials", "author": "Roman YM", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis", "key": "ref11", "unstructured": "Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of coronavirus disease 2019: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2022, 74:1022-9. 10.1093/cid/ciab591", "volume": "74", "year": "2022" }, { "DOI": "10.1016/j.dsx.2021.102186", "article-title": "Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials", "author": "Zein AF", "doi-asserted-by": "publisher", "journal-title": "Diabetes Metab Syndr", "key": "ref12", "unstructured": "Zein AF, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021, 15:102186. 10.1016/j.dsx.2021.102186", "volume": "15", "year": "2021" }, { "DOI": "10.1097/MJT.0000000000001402", "article-title": "Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis and trial sequential analysis to inform clinical guidelines", "author": "Bryant A", "doi-asserted-by": "publisher", "journal-title": "Am J Ther", "key": "ref13", "unstructured": "Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021, 28:e434-60. 10.1097/MJT.0000000000001402", "volume": "28", "year": "2021" }, { "DOI": "10.1016/j.ijantimicag.2024.107248", "article-title": "Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: a systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants", "author": "Hernandez AV", "doi-asserted-by": "publisher", "journal-title": "Int J Antimicrob Agents", "key": "ref14", "unstructured": "Hernandez AV, Liu A, Roman YM, et al.. Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: a systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants. Int J Antimicrob Agents. 2024, 64:107248. 10.1016/j.ijantimicag.2024.107248", "volume": "64", "year": "2024" }, { "DOI": "10.1002/rmv.2265", "article-title": "Ivermectin and outcomes from Covid‐19 pneumonia: a systematic review and meta‐analysis of randomized clinical trial studies", "author": "Hariyanto TI", "doi-asserted-by": "publisher", "journal-title": "Rev Med Virol", "key": "ref15", "unstructured": "Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from Covid‐19 pneumonia: a systematic review and meta‐analysis of randomized clinical trial studies. Rev Med Virol. 2021, 32:e2265. 10.1002/rmv.2265", "volume": "32", "year": "2021" }, { "DOI": "10.1016/j.heliyon.2024.e27647", "article-title": "Ivermectin for treatment of COVID-19: a systematic review and meta-analysis", "author": "Song Z", "doi-asserted-by": "publisher", "journal-title": "Heliyon", "key": "ref16", "unstructured": "Song Z, Shi S, Zhang Y. Ivermectin for treatment of COVID-19: a systematic review and meta-analysis. Heliyon. 2024, 10:e27647. 10.1016/j.heliyon.2024.e27647", "volume": "10", "year": "2024" }, { "DOI": "10.1007/s40261-022-01213-y", "article-title": "The effect of nitazoxanide on the clinical outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials", "author": "Abuelazm M", "doi-asserted-by": "publisher", "journal-title": "Clin Drug Investig", "key": "ref17", "unstructured": "Abuelazm M, Ghanem A, Awad AK, Farahat RA, Labieb F, Katamesh BE, Abdelazeem B. The effect of nitazoxanide on the clinical outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2022, 42:1031-47. 10.1007/s40261-022-01213-y", "volume": "42", "year": "2022" }, { "DOI": "10.1080/14787210.2022.2142117", "article-title": "Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials", "author": "Weng TC", "doi-asserted-by": "publisher", "journal-title": "Expert Rev Anti Infect Ther", "key": "ref18", "unstructured": "Weng TC, Weng TS, Lai CC, Chao CM, Wang JH. Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2022, 20:1615-22. 10.1080/14787210.2022.2142117", "volume": "20", "year": "2022" }, { "DOI": "10.1007/s00228-022-03380-5", "article-title": "Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials", "author": "Martins-Filho PR", "doi-asserted-by": "publisher", "journal-title": "Eur J Clin Pharmacol", "key": "ref19", "unstructured": "Martins-Filho PR, do Nascimento-Júnior EM, Barreto-Alves JA, Fakhouri R, Ferreira LC. Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Eur J Clin Pharmacol. 2022, 78:1813-21. 10.1007/s00228-022-03380-5", "volume": "78", "year": "2022" }, { "key": "ref20", "unstructured": "World Health Organization.. COVID-19 case definition. (2022). Accessed: November 24, 2024: https://who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2." }, { "key": "ref21", "unstructured": "Laboratories with InDRE recognition, to carry out the diagnosis of COVID-19, for epidemiological surveillance purposes (site in Spanish). (2022). Accessed. November 24, 2024: https://www.gob.mx/cms/uploads/attachment/file/688705/LISTADO_DE_LABORATORIOS_QUE_REALIZAN_EL_DIAGNOSTICO_DE_COVID-19...." }, { "DOI": "10.1016/j.jviromet.2020.114008", "article-title": "SARS-CoV-2: comparative analysis of different RNA extraction methods", "author": "Ambrosi C", "doi-asserted-by": "publisher", "journal-title": "J Virol Methods", "key": "ref22", "unstructured": "Ambrosi C, Prezioso C, Checconi P, et al.. SARS-CoV-2: comparative analysis of different RNA extraction methods. J Virol Methods. 2021, 287:114008. 10.1016/j.jviromet.2020.114008", "volume": "287", "year": "2021" }, { "DOI": "10.1007/s40121-020-00324-3", "article-title": "A systematic review of the clinical utility of cycle threshold values in the context of COVID-19", "author": "Rao SN", "doi-asserted-by": "publisher", "journal-title": "Infect Dis Ther", "key": "ref23", "unstructured": "Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020, 9:573-86. 10.1007/s40121-020-00324-3", "volume": "9", "year": "2020" }, { "key": "ref24", "unstructured": "Medscape. ivermectin (Rx). (2021). Accessed: November 24, 2024: https://reference.medscape.com/drug/stromectol-ivermectin-342657." }, { "DOI": "10.1086/428839", "article-title": "Nitazoxanide: a new thiazolide antiparasitic agent", "author": "Fox LM", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis", "key": "ref25", "unstructured": "Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis. 2005, 40:1173-80. 10.1086/428839", "volume": "40", "year": "2005" }, { "DOI": "10.1002/jmv.26880", "article-title": "Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19", "author": "Elalfy H", "doi-asserted-by": "publisher", "journal-title": "J Med Virol", "key": "ref26", "unstructured": "Elalfy H, Besheer T, El-Mesery A, et al.. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021, 93:3176-83. 10.1002/jmv.26880", "volume": "93", "year": "2021" }, { "DOI": "10.1016/j.toxrep.2021.03.003", "article-title": "Use of ivermectin in the treatment of Covid-19: a pilot trial", "author": "Pott-Junior H", "doi-asserted-by": "publisher", "journal-title": "Toxicol Rep", "key": "ref27", "unstructured": "Pott-Junior H, Paoliello MM, Miguel AQ, et al.. Use of ivermectin in the treatment of Covid-19: a pilot trial. Toxicol Rep. 2021, 8:505-10. 10.1016/j.toxrep.2021.03.003", "volume": "8", "year": "2021" }, { "DOI": "10.1016/j.eclinm.2020.100720", "article-title": "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial", "author": "Chaccour C", "doi-asserted-by": "publisher", "journal-title": "EClinicalMedicine", "key": "ref28", "unstructured": "Chaccour C, Casellas A, Blanco-Di Matteo A, et al.. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021, 32:100720. 10.1016/j.eclinm.2020.100720", "volume": "32", "year": "2021" }, { "DOI": "10.1183/13993003.03725-2020", "article-title": "Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial", "author": "Rocco PR", "doi-asserted-by": "publisher", "journal-title": "Eur Respir J", "key": "ref29", "unstructured": "Rocco PR, Silva PL, Cruz FF, et al.. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021, 58:4-6. 10.1183/13993003.03725-2020", "volume": "58", "year": "2021" }, { "DOI": "10.18103/mra.v11i2.3364", "article-title": "Efficacy of nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study", "author": "Silva M", "doi-asserted-by": "publisher", "journal-title": "Med Res Arch", "key": "ref30", "unstructured": "Silva M, Espejo A, Pereyra ML, et al.. Efficacy of nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. Med Res Arch. 2023, 11:2-4. 10.18103/mra.v11i2.3364", "volume": "11", "year": "2023" }, { "DOI": "10.24875/hgmx.20000078", "article-title": "Biomarkers associated with COVID-19 disease progression", "author": "Ponti G", "doi-asserted-by": "publisher", "journal-title": "Crit Rev Cin Lab Sci", "key": "ref31", "unstructured": "Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Cin Lab Sci. 2021, 57:389-99. 10.24875/hgmx.20000078", "volume": "57", "year": "2021" }, { "DOI": "10.1136/openhrt-2020-001350", "article-title": "Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19", "author": "DiNicolantonio JJ", "doi-asserted-by": "publisher", "journal-title": "Open Heart", "key": "ref32", "unstructured": "DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart. 2020, 7:26-8. 10.1136/openhrt-2020-001350", "volume": "7", "year": "2020" }, { "DOI": "10.1016/j.blre.2020.100761", "article-title": "Coagulation and anticoagulation in COVID-19", "author": "Hadid T", "doi-asserted-by": "publisher", "journal-title": "Blood Rev", "key": "ref33", "unstructured": "Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021, 47:100761. 10.1016/j.blre.2020.100761", "volume": "47", "year": "2021" }, { "DOI": "10.24875/RIC.20000211", "article-title": "Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico City: a prospective cohort study", "author": "Ortiz-Brizuela E", "doi-asserted-by": "publisher", "journal-title": "Rev Invest Clin", "key": "ref34", "unstructured": "Ortiz-Brizuela E, Villanueva-Reza M, González-Lara MF, et al.. Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico City: a prospective cohort study. Rev Invest Clin. 2020, 72:165-77. 10.24875/RIC.20000211", "volume": "72", "year": "2020" }, { "DOI": "10.1016/j.chest.2020.10.009", "article-title": "Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the Ivermectin in COVID Nineteen Study", "author": "Rajter JC", "doi-asserted-by": "publisher", "journal-title": "Chest", "key": "ref35", "unstructured": "Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the Ivermectin in COVID Nineteen Study. Chest. 2021, 159:85-92. 10.1016/j.chest.2020.10.009", "volume": "159", "year": "2021" }, { "DOI": "10.1016/j.ijid.2020.11.191", "article-title": "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness", "author": "Ahmed S", "doi-asserted-by": "publisher", "journal-title": "Int J Infect Dis", "key": "ref36", "unstructured": "Ahmed S, Karim MM, Ross AG, et al.. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021, 103:214-6. 10.1016/j.ijid.2020.11.191", "volume": "103", "year": "2021" }, { "DOI": "10.1186/s12916-020-01726-3", "article-title": "COVID-19 length of hospital stay: a systematic review and data synthesis", "author": "Rees EM", "doi-asserted-by": "publisher", "journal-title": "BMC Med", "key": "ref37", "unstructured": "Rees EM, Nightingale ES, Jafari Y, et al.. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020, 18:270. 10.1186/s12916-020-01726-3", "volume": "18", "year": "2020" }, { "DOI": "10.5281/zenodo.3926806", "article-title": "COVID-19 in Mexico: epidemiological panorama (article in Spanish)", "author": "Padilla-Santamaría F", "doi-asserted-by": "publisher", "journal-title": "Revista Cadena de Cerebros", "key": "ref38", "unstructured": "Padilla-Santamaría F, Maya-Franco L, Ferman-Cano F. COVID-19 in Mexico: epidemiological panorama (article in Spanish). Revista Cadena de Cerebros. 2020, 4:31-42. 10.5281/zenodo.3926806", "volume": "4", "year": "2020" }, { "article-title": "Mortality from COVID-19 in Mexico. Preliminary notes for a sociodemographic profile", "author": "Bringas HH", "journal-title": "Notas de Coyuntura del CRIM", "key": "ref39", "unstructured": "Bringas HH. Mortality from COVID-19 in Mexico. Preliminary notes for a sociodemographic profile. Notas de Coyuntura del CRIM. 2020, 36:1-7.", "volume": "36", "year": "2020" }, { "DOI": "10.1007/s43440-021-00245-z", "article-title": "The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis", "author": "Kow CS", "doi-asserted-by": "publisher", "journal-title": "Pharmacol Rep", "key": "ref40", "unstructured": "Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021, 73:1473-9. 10.1007/s43440-021-00245-z", "volume": "73", "year": "2021" }, { "DOI": "10.1093/ofid/ofab358", "article-title": "Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection", "author": "Hill A", "doi-asserted-by": "publisher", "journal-title": "Open Forum Infect Dis", "key": "ref41", "unstructured": "Hill A, Garratt A, Levi J, et al.. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect Dis. 2021, 8:ofab358. 10.1093/ofid/ofab358", "volume": "8", "year": "2021" }, { "key": "ref42", "unstructured": "FDA. know your treatment options for COVID-19. (2023). Accessed: November 15, 2024: https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19#:~:text=If%20you%20are%20infected...." }, { "DOI": "10.3947/ic.2020.0126", "article-title": "Ruxolitinib and the mitigation of severe COVID-19: a systematic review and meta-analysis", "author": "Quiros JR", "doi-asserted-by": "publisher", "journal-title": "Infect Chemother", "key": "ref43", "unstructured": "Quiros JR, Ross-Comptis J, Hathaway D 3rd, et al.. Ruxolitinib and the mitigation of severe COVID-19: a systematic review and meta-analysis. Infect Chemother. 2021, 53:436-48. 10.3947/ic.2020.0126", "volume": "53", "year": "2021" } ], "reference-count": 43, "references-count": 43, "relation": {}, "resource": { "primary": { "URL": "https://www.cureus.com/articles/237234-clinical-experience-with-ivermectin-and-nitazoxanide-in-the-management-of-covid-19-among-mexican-out--and-inpatients" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients", "type": "journal-article" }